A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT07776743 · RECRUITING

Trial details

NCT number: NCT07776743
Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsing-remitting Multiple Sclerosis (RRMS)

Start date: 2026-08-01
Primary completion: 2028-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.